Trial · NCT02881957
Hypovitaminosis D in Neurocritical Patients
NCT02881957, Phase 2, Phase 3, Completed, University of Utah; results first posted 2020-08-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hypovitaminosis D in Neurocritical Patients. Trials, record NCT02881957. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02881957
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hypovitaminosis D in Neurocritical Patients
- NCT number
- NCT02881957
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 274 participants, actual
- Lead sponsor
- University of Utah
- Conditions
- Craniocerebral Trauma, Intracranial Aneurysm, Brain Neoplasms, Spinal Cord Injuries, Seizures, Meningitis, Stroke, Intracranial Hemorrhages, Critical Illness, Vitamin d Deficiency
- Interventions
- Cholecalciferol, Placebo
- First posted
- 2016-08-29
- Last updated
- 2022-06-15
- Results first posted
- 2020-08-17
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Intent-to-treat Hospital Length-of-stay | Until discharge | Intent-to-treat hospital length-of-stay |
| Primary | As-treated Hospital Length of Stay | Until discharge | Two-sided t-test evaluated comparing length of stay in vitamin D3 vs. placebo treated patients utilizing patients after randomization, factoring excluded patients (e.g., as-treated) using a p\<0.05 as significant. |
| Secondary | Intent-to-treat ICU Length of Stay | Until discharge | Two-sided t-test evaluated comparing length of stay within the ICU specifically in vitamin D3 vs. placebo treated patients utilizing patients after randomization (e.g., intent-to-treat) using a p\<0.05 as significant. |
| Secondary | As-treated ICU Length of Stay | Until discharge | Two-sided t-test evaluated comparing length of stay within the ICU specifically in vitamin D3 vs. placebo treated patients utilizing patients after randomization but excluding patients who did not receive treatment (e.g., as-treated) using a p\<0.05 as significant. |
| Secondary | In-hospital Mortality | Until discharge | In-hospital mortality |
| Secondary | Number of Participants With Study Drug Related Adverse Events | Until discharge | The occurrence of patients who suffered mortality, adverse events or severe adverse events, related specifically to the study drug was monitored. Severe adverse events are defined using common terminology criteria for adverse events (CTCAE) grade 3 or higher specific to vitamin D from time of study drug administration to discharge. |
| Secondary | Number of Participants With Sepsis | Until discharge | Diagnosis of sepsis |
| Secondary | Number of Participants With Pneumonia | Until discharge | Pneumonia diagnosis |
| Secondary | Number of Participants With Urinary Tract Infection | Until discharge | Urinary tract infection diagnosis |
| Secondary | Number of Participants With Deep Vein Thrombosis | Until discharge | Deep vein thrombosis diagnosis |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Intent-to-treat Hospital Length-of-stay | Until discharge | days | MEAN | |
| PRIMARY | As-treated Hospital Length of Stay | Until discharge | days | MEAN | |
| SECONDARY | Intent-to-treat ICU Length of Stay | Until discharge | days | MEAN | |
| SECONDARY | As-treated ICU Length of Stay | Until discharge | days | MEAN | |
| SECONDARY | In-hospital Mortality | Until discharge | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Study Drug Related Adverse Events | Until discharge | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Sepsis | Until discharge | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Pneumonia | Until discharge | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Urinary Tract Infection | Until discharge | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Deep Vein Thrombosis | Until discharge | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Intent-to-treat Hospital Length-of-stay | Vitamin D3 | 10.9 | Standard Deviation 15.6 | days | |
| Intent-to-treat Hospital Length-of-stay | Placebo | 9.1 | Standard Deviation 7.9 | days | |
| As-treated Hospital Length of Stay | Vitamin D3 | 10.4 | Standard Deviation 14.5 | days | |
| As-treated Hospital Length of Stay | Placebo | 9.1 | Standard Deviation 7.9 | days | |
| Intent-to-treat ICU Length of Stay | Vitamin D3 | 6.4 | Standard Deviation 9.8 | days | |
| Intent-to-treat ICU Length of Stay | Placebo | 5.4 | Standard Deviation 6.4 | days | |
| As-treated ICU Length of Stay | Vitamin D3 | 5.8 | Standard Deviation 7.5 | days | |
| As-treated ICU Length of Stay | Placebo | 5.4 | Standard Deviation 6.4 | days | |
| In-hospital Mortality | Vitamin D3 | 11 | Participants | ||
| In-hospital Mortality | Placebo | 13 | Participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 136 | |
| Overall Study | STARTED | Vitamin D3 | 138 | |
| Overall Study | COMPLETED | Placebo | 133 | |
| Overall Study | COMPLETED | Vitamin D3 | 134 | |
| Overall Study | NOT COMPLETED | Placebo | 3 | |
| Overall Study | NOT COMPLETED | Vitamin D3 | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vitamin D3 | 11 | 134 |
| Total, all-cause mortality | Placebo | 13 | 133 |
| Total, other adverse events | Vitamin D3 | 0 | 134 |
| Total, other adverse events | Placebo | 0 | 133 |
| Total, serious adverse events | Vitamin D3 | 0 | 134 |
| Total, serious adverse events | Placebo | 0 | 133 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons8
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Vitamin D3 vs Placebo: Number of Participants With Sepsis | Trial comparisons |
| Vitamin D3 vs Placebo: In-hospital Mortality | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Deep Vein Thrombosis | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Study Drug Related Adverse Events | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Pneumonia | Trial comparisons |
| Vitamin D3 vs Placebo: Number of Participants With Urinary Tract Infection | Trial comparisons |
| Vitamin D3 vs Placebo: deaths from any cause | Trial comparisons |
| Vitamin D3 vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02881957
GET https://conductscience.org/api/trials/v1/NCT02881957/registered